Fang Sheen-Yie, Perng Diahn-Warng, Lee J Yu-Yun, Lin Ding-Yu, Huangs Chih-Yang
Department of Otolaryngology, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China.
Chin J Physiol. 2010 Aug 31;53(4):199-207. doi: 10.4077/cjp.2010.amk007.
Levocetirizine has been shown in observational studies in the west as an effective and satisfactory therapy for patients with allergic respiratory and skin disease. An open-label, multicentre observational study was conducted to investigate the patients' perception of levocetirizine in the treatment of allergic rhinitis (AR) and urticaria in Taiwanese patients. Three hundred and thirty-three patients (236 AR and 97 urticaria patients) attending out-patient clinics of medical centres across Taiwan were included in the study. Patients were treated with levocetirizine 5 mg once daily (AR patients for 2-4 weeks and urticaria patients for 2-6 weeks) and at the end of treatment, they evaluated for symptoms of disease, perception of change in symptoms, global efficacy and tolerability, global preference over previous antiallergic treatment, change in quality of sleep/daily activities, and safety and adverse events (AEs). Levocetirizine markedly improved the symptoms of AR and urticaria; with 70-75% of AR patients and 60-80% of urticaria patients reporting complete or marked improvements in individual symptoms. Asthma symptoms were completely or markedly improved in 44% of patients with AR and concomitant asthma. A majority of the patients was satisfied with levocetirizine therapy and 50-70% indicated preference for levocetirizine over previous therapy. Overall, 50-74% of all patients perceived improvements in quality of sleep/daily activities and 50-65% of the patients rated the onset of action for levocetirizine as very rapid or rapid. Somnolence was the most common AE, reported by 7.4% of AR and 7.0% of urticaria patients. The results of this study indicated that levocetirizine is an effective and satisfactory therapy for the management of allergic respiratory and skin disease in Taiwanese subjects.
在西方的观察性研究中，左西替利嗪已被证明是治疗过敏性呼吸道和皮肤疾病患者的一种有效且令人满意的疗法。开展了一项开放标签、多中心观察性研究，以调查台湾患者对左西替利嗪治疗过敏性鼻炎（AR）和荨麻疹的看法。纳入了台湾各地医疗中心门诊的333例患者（236例AR患者和97例荨麻疹患者）。患者接受每日一次5mg左西替利嗪治疗（AR患者治疗2 - 4周，荨麻疹患者治疗2 - 6周），治疗结束时，评估疾病症状、症状变化感知、总体疗效和耐受性、相对于先前抗过敏治疗的总体偏好、睡眠/日常活动质量变化以及安全性和不良事件（AE）。左西替利嗪显著改善了AR和荨麻疹的症状；70 - 75%的AR患者和60 - 80%的荨麻疹患者报告个体症状完全或显著改善。44%的AR合并哮喘患者的哮喘症状完全或显著改善。大多数患者对左西替利嗪治疗满意，50 - 70%的患者表示比起先前治疗更喜欢左西替利嗪。总体而言，50 - 74%的所有患者感觉睡眠/日常活动质量有所改善，50 - 65%的患者将左西替利嗪的起效速度评为非常快或快。嗜睡是最常见的AE，7.4%的AR患者和7.0%的荨麻疹患者报告出现嗜睡。本研究结果表明，左西替利嗪是治疗台湾受试者过敏性呼吸道和皮肤疾病的一种有效且令人满意的疗法。
